Neurology perspectives最新文献

Multiple sclerosis and rheumatic diseases: Rheumatoid arthritis, antiphospholipid syndrome, and systemic lupus erythematosus 多发性硬化和风湿性疾病：类风湿关节炎、抗磷脂综合征和系统性红斑狼疮

Neurology perspectives Pub Date : 2025-07-01 DOI: 10.1016/j.neurop.2025.100197

M.A. Hernández , B. González , Y. Contreras , L.M. Armas

引用次数: 0

Inflammatory bowel disease and multiple sclerosis 炎性肠病和多发性硬化症

Neurology perspectives Pub Date : 2025-07-01 DOI: 10.1016/j.neurop.2025.100199

M. Dominguez-Gallego, V. Meca-Lallana, C. Ana Belén

{"title":"Inflammatory bowel disease and multiple sclerosis","authors":"M. Dominguez-Gallego, V. Meca-Lallana, C. Ana Belén","doi":"10.1016/j.neurop.2025.100199","DOIUrl":"10.1016/j.neurop.2025.100199","url":null,"abstract":"<div><h3>Introduction</h3><div>Inflammatory bowel disease (IBD), which mainly includes Crohn’s disease and ulcerative colitis, is characterised by chronic inflammation in the gastrointestinal tract, triggered and perpetuated by an altered immune response. An association has been established between this condition and other autoimmune diseases, including multiple sclerosis (MS). The prevalence of MS in patients with IBD is 0.2%; the association between the 2 conditions is attributed to shared genetic and environmental pathogenic mechanisms.</div></div><div><h3>Development</h3><div>In patients presenting with both diseases, several considerations should be taken into account when selecting the most appropriate treatment. Regarding MS treatment, interferons have been associated with worsening of IBD symptoms, whereas such monoclonal antibodies as rituximab and ocrelizumab may cause gastrointestinal toxicity, and alemtuzumab is not recommended due to increased risk of autoimmune complications. Natalizumab and sphingosine 1-phosphate modulators, such as ozanimod, constitute safer and more effective options for patients with IBD.</div><div>Regarding treatments for IBD, TNF-α antagonists are contraindicated in patients with MS due to the associated risk of central nervous system demyelination. Vedolizumab and ustekinumab are the recommended alternatives in these cases.</div></div><div><h3>Conclusions</h3><div>Though weak, the association between IBD and MS should be acknowledged; preferably, management of these patients should include medications that treat both conditions simultaneously.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100199"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Other autoimmune diseases and multiple sclerosis 其他自身免疫性疾病和多发性硬化症

Neurology perspectives Pub Date : 2025-07-01 DOI: 10.1016/j.neurop.2025.100196

S. Martínez-Yélamos , Á. Pérez-Sempere

{"title":"Other autoimmune diseases and multiple sclerosis","authors":"S. Martínez-Yélamos , Á. Pérez-Sempere","doi":"10.1016/j.neurop.2025.100196","DOIUrl":"10.1016/j.neurop.2025.100196","url":null,"abstract":"<div><h3>Introduction</h3><div>This study explores the association between multiple sclerosis (MS) and other autoimmune diseases, including myasthenia gravis (MG), autoimmune encephalitis (AE), and demyelinating polyneuropathies such as combined central and peripheral demyelination (CCPD), chronic inflammatory demyelinating polyneuropathy (CIDP), and Guillain-Barré syndrome (GBS).</div></div><div><h3>Development</h3><div>For each association, we discuss epidemiological data, clinical features, and therapeutic management strategies. The prevalence of MG is higher in patients with MS than in the general population. Certain MS treatments, such as alemtuzumab, may increase the risk of developing MG or AE. Among the most suitable therapeutic options for patients with coexisting MG or AE are azathioprine and rituximab. Antibody-mediated AE associated with MS is managed similarly to AE unrelated to MS. The association between MS and CIDP contributes to neurological disability and is likely underdiagnosed.</div></div><div><h3>Conclusions</h3><div>The coexistence of MS with other autoimmune diseases presents significant diagnostic and therapeutic challenges. Awareness of the therapeutic options available for each association is essential in order to identify the most appropriate approach in each case. Early recognition and adequate management of these comorbidities may improve clinical outcomes and enhance patients’ quality of life.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100196"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiple sclerosis and rheumatic diseases: Behçet disease, sarcoidosis, and Sjögren syndrome 多发性硬化症和风湿病：behaperet病、结节病和Sjögren综合征

Neurology perspectives Pub Date : 2025-07-01 DOI: 10.1016/j.neurop.2025.100198

M.A. Hernández , Y. Contreras , B. González , L.M. Armas

{"title":"Multiple sclerosis and rheumatic diseases: Behçet disease, sarcoidosis, and Sjögren syndrome","authors":"M.A. Hernández , Y. Contreras , B. González , L.M. Armas","doi":"10.1016/j.neurop.2025.100198","DOIUrl":"10.1016/j.neurop.2025.100198","url":null,"abstract":"<div><h3>Introduction</h3><div>Multiple sclerosis can be associated with a range of rheumatic processes. Behçet disease is a relapsing, multisystemic, immune-mediated chronic vasculitic disorder of unknown aetiology, whose symptoms overlap with those of many autoinflammatory processes. Sarcoidosis is a universally distributed multisystem granulomatous disease. Sjögren syndrome is a chronic, autoimmune, inflammatory disease characterised by lymphocytic infiltration in exocrine glands, which causes xerostomia (dry mouth) and xerophthalmia (dry eyes). The most frequent extraglandular manifestations of the syndrome are musculoskeletal problems.</div></div><div><h3>Development</h3><div>We describe the most significant neurological complications of these rheumatic diseases, as well as the pharmacological treatments that may be indicated for these conditions and the possible contraindications in patients receiving treatment for multiple sclerosis.</div></div><div><h3>Conclusions</h3><div>We provide a series of recommendations for the treatment of patients with multiple sclerosis who also present with Behçet disease, sarcoidosis, or Sjögren syndrome. Co-presence of any of these rheumatic diseases constitutes a contraindication for some treatments.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100198"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144557469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of the most prevalent autoimmune diseases co-occurring with Multiple Sclerosi 多发性硬化症并发的最常见自身免疫性疾病的管理

Neurology perspectives Pub Date : 2025-07-01 DOI: 10.1016/j.neurop.2025.100194

A.B. Caminero

引用次数: 0

Autoimmune eye diseases in multiple sclerosis 多发性硬化症中的自身免疫性眼病

Neurology perspectives Pub Date : 2025-07-01 DOI: 10.1016/j.neurop.2025.100195

M.L. Martínez Ginés , P. Rojas Lozano

{"title":"Autoimmune eye diseases in multiple sclerosis","authors":"M.L. Martínez Ginés , P. Rojas Lozano","doi":"10.1016/j.neurop.2025.100195","DOIUrl":"10.1016/j.neurop.2025.100195","url":null,"abstract":"<div><h3>Introduction</h3><div>The eye is a complex organ that can present complications related to autoimmune diseases, including multiple sclerosis (MS). Ocular manifestations may act as early indicators of autoimmune diseases, and their early diagnosis and treatment are essential to guaranteeing patients' quality of life. This review analyses the main autoimmune eye diseases associated with MS, focusing on intermediate uveitis and its personalised management.</div></div><div><h3>Development</h3><div>MS-associated uveitis includes various forms of intraocular inflammation affecting different areas of the eye. The relationship between MS and uveitis is complex and involves shared immunological mechanisms and diagnostic and therapeutic challenges. The clinical presentation of uveitis varies from asymptomatic forms to severe vision-threatening complications. The treatment of uveitis involves careful assessment and the consideration of immunomodulatory or immunosuppressive treatment with a view to controlling inflammation and preventing visual sequelae.</div></div><div><h3>Conclusions</h3><div>Treatment of MS-related uveitis is complex and requires a multidisciplinary approach. Advances in immunomodulatory therapy offer new treatment options, as well as challenges related to adverse reactions and disease management. Further research is needed to better understand the relationship between MS and eye diseases, and to optimise therapeutic strategies and improve patients' visual and neurological outcomes.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100195"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144536222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Autoimmune skin diseases in multiple sclerosis 多发性硬化症中的自身免疫性皮肤病

Neurology perspectives Pub Date : 2025-07-01 DOI: 10.1016/j.neurop.2025.100200

M. Roncero Riesco , A. Cabanillas Cabral , Y. El Berdei Montero

{"title":"Autoimmune skin diseases in multiple sclerosis","authors":"M. Roncero Riesco , A. Cabanillas Cabral , Y. El Berdei Montero","doi":"10.1016/j.neurop.2025.100200","DOIUrl":"10.1016/j.neurop.2025.100200","url":null,"abstract":"<div><h3>Introduction</h3><div>Autoimmune dermatological diseases have a prevalence greater than 2% in the general population, sometimes as a primary disorder and other times within a context of systemic involvement. Comorbidity with multiple sclerosis (MS) has been described, particularly in the case of psoriasis and bullous pemphigoid, and to a lesser extent in pemphigus vulgaris and other autoimmune skin diseases.</div></div><div><h3>Development</h3><div>Psoriasis is the autoimmune skin disease for which the most evidence is available on this association, with increased risk in patients with MS. Both disorders probably have common pathophysiological mechanisms. The joint treatment of both diseases will depend on the degree of activity of each one, but in general, it is recommended for patients with MS and psoriasis to avoid interferons, teriflunomide, and anti-CD20 monoclonal antibodies, whereas fumarates and S1P receptor antagonists are recommended. TNF-α inhibitors are formally contraindicated in MS. In the case of bullous pemphigoid, pemphigus vulgaris, and other less common autoimmune dermatological diseases, the relationship with MS is not so clearly established, although an association between the first 2 and neurological diseases, including MS, has been described. Treatment is based on corticotherapy, and classic immunosuppressants or rituximab may be combined, which represent an alternative for joint treatment.</div></div><div><h3>Conclusions</h3><div>Comorbidity between MS and autoimmune dermatological disorders, and especially psoriasis, requires a joint approach, avoiding treatments that may aggravate one or the other disorders.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100200"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144535783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Taste disorders due to unilateral upper molar extraction in juvenile and adult albino rats 幼年和成年白化大鼠单侧上磨牙拔牙引起的味觉障碍

Neurology perspectives Pub Date : 2025-06-19 DOI: 10.1016/j.neurop.2025.100203

A. Gutiérrez-Patiño Paúl, E. Aguirre-Siancas

{"title":"Taste disorders due to unilateral upper molar extraction in juvenile and adult albino rats","authors":"A. Gutiérrez-Patiño Paúl, E. Aguirre-Siancas","doi":"10.1016/j.neurop.2025.100203","DOIUrl":"10.1016/j.neurop.2025.100203","url":null,"abstract":"<div><h3>Introduction</h3><div>The sense of taste is fundamental to life; some studies have revealed a link between dental deafferentation (DD) by upper molar extraction and taste abnormalities in rats. However, no studies have been found that evaluate these variables using the Taste Reactivity Test (TRT).</div></div><div><h3>Methods</h3><div>Forty male Wistar rats (20 juveniles and 20 adults) were used and assigned to a control and experimental group. Both groups were fitted with cannulae for TRT, while rats in the experimental group also had their right upper molars extracted. Using an ingestive solution (1 M sucrose) and an aversive solution (3 mM denatonium benzoate [BD]), TRT was performed on days 1, 7, 14, and 21. Body and orofacial reactions were recorded and scored.</div></div><div><h3>Results</h3><div>DD influences ingestive responses in juvenile rats at days 7, 14, and 21; however, it only affects aversive responses at day 21. In adult rats, it influences ingestive responses at days 14 and 21, although it only affects aversive responses at day 14. When comparing ingestive and aversive responses between juvenile and adult rats in the experimental group, differences were identified in ingestive responses at days 7 and 14.</div></div><div><h3>Conclusions</h3><div>In juvenile and adult rats, upper molar extraction has a negative influence on ingestive and aversive responses. In addition, compared to adult rats, it has a negative effect on ingestive responses in juvenile rats.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 4","pages":"Article 100203"},"PeriodicalIF":0.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144557468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cough headache associated with CANVAS: A case report 与CANVAS相关的咳嗽头痛1例报告

Neurology perspectives Pub Date : 2025-06-14 DOI: 10.1016/j.neurop.2025.100202

E. Martínez-Campos , M. San Miguel , M. Martín Bujanda

引用次数: 0

A case of primary HIV infection presenting as Guillain-Barré syndrome: Could it be a separate entity? 1例原发性HIV感染表现为格林-巴-罗综合征：它可能是一个单独的实体吗？

Neurology perspectives Pub Date : 2025-06-14 DOI: 10.1016/j.neurop.2025.100201

D. López de Mota Sánchez, M. de la Calle Cuevas, L. Olivié-García, I. Zamarbide Capdepon

引用次数: 0